Table 3. Predictors of Cancer-Specific Death in Patients with Metastatic Prostate Cancer.
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| HR | (95% CI) | p value | HR | (95% CI) | p value | |
| Age | 1.007 | (0.981-1.023) | 0.547 | |||
| Body mass index | 1.017 | (0.948-1.091) | 0.642 | |||
| ECOG PS (≥1) | 2.501 | (1.609-3.891) | <0.001 | 1.006 | (1.002-1.011) | 0.008 |
| CCI (≥4) | 1.045 | (0.896-1.212) | 0.575 | |||
| VAS pain score (≥1) | 2.501 | (1.803-3.939) | <0.001 | 1.861 | (1.177-2.910) | 0.002 |
| PSA | 1.365 | (0.853-2.185) | 0.194 | |||
| PSA nadir | 1.002 | (1.001-1.002) | <0.001 | 1.002 | (1.001-1.002) | 0.001 |
| Hemoglobin | 1.161 | (0.567-2.376) | 0.719 | |||
| ALP | 1.001 | (1.000-1.002) | 0.073 | |||
| Gleason score (≥8) | 2.121 | (1.318-3.409) | 0.002 | 1.935 | (0.918-4.079) | 0.083 |
| T stage (≥T3) | 1.409 | (0.754-2.948) | 0.251 | |||
| Progression to CRPC | 1.512 | (0.786-3.106) | 0.261 | |||
| Time to CRPC progression | 1.084 | (0.981-1.201) | 0.132 | |||
| Metastatic site | ||||||
| Viscera | 1 | (Reference) | 1 | (Reference) | ||
| Bone | 2.286 | (1.537-3.399) | <0.001 | 1.758 | (1.152-2.683) | 0.009 |
ALP, alkaline phosphatase; CCI, Charlson Comorbidity Index; CRPC, castration-resistant prostate cancer; ECOG PS, Eastern Cooperative Oncology Group performance score; PSA, prostate-specific antigen; VAS, Visual Analogue Scale; HR, hazard ratio; CI, confidence interval.